Originally published by Alkaway’s Co-founder, Ian Hamilton on August 14th, 2017.
It causes a chronic inflammatory response. The body’s own immune cells attacking the joint, including cartilage and bone. No wonder it hurts!
It doesn’t cease spontaneously. The international research team headed by the rheumatologist Dr Andreas Ramming at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) has now managed to identify an immune system cell type that can be used in a targeted attempt to control the inflammatory response in arthritis patients. The results obtained by the research team at Department of Medicine 3 - Rheumatology and Immunology of Universitätsklinikum Erlangen have been published in Nature Medicine.
In Germany alone, close to a million people, mostly women, suffer from rheumatoid arthritis. The persistent inflammation damages the joints and bones. Patients suffer pain and it restricts their mobility.
“A particularly worrying aspect for those affected is the fact that the inflammatory response in joints is exceptionally chronic and thus usually requires lifelong treatment.” explains Prof. Georg Schett, director of the Department of Medicine 3.
We have cells known as innate lymphoid cells which usually manage the resolution of inflammations. However, to date, little has been known about how inflammations clear up and why this process doesn’t work in those suffering from rheumatism.
Now a joint project involving researchers in London, Barcelona, Zurich, Indianapolis and Dublin has now enabled the researchers in Erlangen to solve this mystery. According to Simon Rauber, an immunologist in Erlangen and primary author of the study, a previously inadequately studied cell population of the immune system called innate lymphoid cells plays a major role in the resolution of inflammations.
The Natural Anti Inflammatory Cells Go on Holiday.
It appears innate lymphoid cells go into a kind of ‘hibernation’ in patients with rheumatism.
In patients suffering from rheumatoid arthritis, these innate lymphoid cells are in a state of what can only be described as hibernation. So inflammation persists. When innate lymphoid cells are ‘woken up’, this puts a stop to the inflammation and to the damage to the joint. The discovery of this important mechanism could provide the opportunity to develop completely new options for treating chronic inflammatory diseases. Which is good news, and bad news.
Good news that this new approach has been identified.
Bad news that we’ll probably have to wait a decade to see any result from mainstream science.
Even now, measuring the number of innate lymphoid cells in the blood makes it possible to at least provide a prognosis of the effects of treatment. If there are only a few innate lymphoid cells in the blood, the disease may flare up and the joint may be further damaged. However, resolution of inflammation is associated with an elevation in the number of these cells. The measurement of blood levels makes it possible to initiate individual, more targeted treatment at an early stage, thus preventing another flare-up of the disease.
“These findings will make it possible to significantly improve the quality of treatment of rheumatoid arthritis in future with the help of innate lymphoid cells,” says Dr Ramming.
“So it often appears to me the natural inflammation cycle, the cycle of events our body goes through to alleviate inflammation is ignored by conventional science because conventional science is supported primarily by ‘Big Pharma’. And Big Pharma isn’t interested in a solution that prevents the sale of a drug they make, which alleviates pain but does not heal. Today i heard that prescription opioids have now overtaken Heroin in accidental deaths. I don’t like to act as if we are victims but it’s hard to see why a corporation larger than many countries would change the way it sees scientific research. A great example is molecular hydrogen. All research on its very broad spectrum benefits were undertaken in Japan and it wasn’t until 2007 that any Western journal decided to publish anything on its results. Today, there are over 700 studies over 150+ disease modalities.” ~ Ian Hamilton
The reason you won’t see it? It’s simple to produce, it can’t be patented and therefore is not eligible for Big Pharma’s profit oriented product range. We get amazing stories from users every day, and if you are one of the millions of sufferers we strongly suggest you check the Molecular Foundation Foundation’s non-Profit Website here, where you can see the studies yourself. We are not permitted to make any claims of therapeutic effects of molecular hydrogen, but take a look at our website and judge for yourself if it’s worth a try.
All I can say is at age 71, I Love H2
Materials provided by University of Erlangen-Nuremberg